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Abstract. Serial passage of a multidrug-resistant clone of Plasmodium fakiparum in
concentrations of mefloquine hydrochloride ranging from 30 to 2,400 ng/ml resulted in
thederivationofincreasinglyresistantparasitelinesinvitro.Parasitelinesisolatedin
mefloquineconcentrationsgreaterthan300 ng/mldemonstratedincreasedvacuolization,
enhanced pigment production, and increased growth rates as compared with the progenitor
clone, W2-mef. Although microdilution incorporation assays demonstrated that the 50%
inhibitory concentration (IC50)of mefloquine were similar for all lines, the IC@, IC95, and
IC99 levels were significantly increased. Growth rate assays performed in 5% hematocrit
suspensions demonstrated different levels of mefloquine resistance among these lines. Un
der these conditions the most resistant line, Mef 2.4, grew efficiently in approximately 10-
fold higher concentrations of mefloquine than the progenitor clone W2-mef. Analysis of
drug susceptibility profiles to mefloquine hydrochloride, chloroquine diphosphate, quinine
sulfate, and halofantrine hydrochloride indicated that selection for high levels of mefloquine
resistance had resulted in significant increases in resistance to halofantrine and increased
sensitivity to chloroquine. The phenotypic changes demonstrated in the most resistant line,
Mef 2.4, reflect a multidrug resistantâ€”likephenotype, and appear to mimic changes recently
reported in drug susceptibility profiles of recrudescent isolates following mefloquine treat
ment failures in Thailand.
Plasmodiumfakiparum, the cause of the most
lethal form of human malaria, is widespread
throughout the tropical world and is one of the
most challenging issues in modern tropical health.
Since vaccines are not available, chemotherapy
represents one of the few methods of control for
the 1.6 billion humans at risk of infection.' Me
floquine (LariamÂ®; Hoffman LaRoche, Nutley,
NJ) has been approved for chemoprophylaxis
and chemotherapy for those at risk of infection
with chloroquine-resistant or multiple drug-re
sistant strains of P.fakiparum.2 Reports of treat
ment failures from Thailand,36 naturally occur
ring foci of resistance in the Philippines and West
Africa,7'8 the induction of resistance in cloned
parasites in vitro,9' 10and possible cross-resis
tance to quinine and halofantrine, however, cast
doubt on the long-term efficacy of meflo
quine,6â€• or any of the existing antimalarials,
against drug-resistant P. fakiparum.
The genetic mechanisms that mediate resis
tance to mefloquine are poorly understood. Ro
dent malaria easily developed resistance to me
floquine, especially when chloroquine resistance
was derived first.'2' 13 A four- to six-fold in
creased resistance to mefloquine was readily de
veloped in vitro from a clonal population of P.
fakiparum by continuous drug pressure. The
clonal line exhibited two-fold increased resis
tance to halofantrine and increased susceptibility
to chloroquine.'Â° In addition, mefloquine resis
tance in P. fakiparum in vitro and P. yoelii in
vivo were reversed by the neuroleptic drug pen
fluridol.'3â€•4These findings have led to the sug
gestion that mefloquine resistance may be phe
notypically similar to the enhanced drug effiux
demonstrated by multidrug-resistant (MDR) tu
mor cell lines. Resistance in these MDR cell lines
is mediated by the activity of an ATP-dependent
effiux pump termed the P-glycoprotein.'5â€•6
Recent evidence suggests that mefloquine re
sistance may also be mediated by point muta
tions and/or gene amplification events in a P-gly
coprotein homolog, the pfmdrl gene, and in
perhaps one or more additional genes.'4â€•7'18
mefloquine resistance phenotype, however, was
not linked to the amplifiedpfmdrl gene following
genetic analysis,'9 indicating that the molecular
basis for mefloquine and chloroquine resistance
has not been established and will require addi
tional study. In this paper, we report the isolation







Reed Army Institute of Research (WRAIR),
(Washington, DC). Stock solutions were pre
pared by dissolving mefloquine hydrochloride in
70% ethanol to give a concentration of 1 mg/ml.
The solution was incubated at 37Â°Cfor 30 mm
and stored at 4Â°Cprotected from light. The ap
propriate concentration ofstock solution was di
luted into medium daily for parasite cultivation
in the presence of drug.
The original W2-mef line had been selected
for resistance to 40 ng/ml of mefloquine.'Â° To
select for increased mefloquine resistance, W2-
mef was continuously exposed to 30 ng/ml of
mefloquine until the clone demonstrated mor
phology and growth rates equivalent to the pa
rental line by microscopic examination. By in
creasing the concentration by 5â€”10ng/ml
increments, lines were derived that were resistant
to 55 ng/ml of mefloquine. Continuous drug
pressure protocols were unsuccessful in selecting
for resistance greater than 55 ng/ml.
Protocols were then developed for selection of
increased resistance using modifications of tech
niques described for the selection for highly re
sistant MDR tumor cell lines and rodent malar
25 Wgh.4ose relapse protocols were initiated
as follows. Parasites were cultivated in the pres
ence of drug until no parasites were detected on
a thin smear, then drug pressure was discontin
ued. Upon demonstration of healthy ring for
mation and parasite growth equivalent to con
trols, cultures were again pressured 3â€”5times
with the same concentration of drug until a cul
ture was derived that tolerated a higher meflo
quine dosage than the parental line as assayed
by smear morphology. Parasite lines were de
veloped as described above at each progressively
higher concentration until lines that tolerated 75,
100, 150, 300, 400, 1,200, and 2,400 ng/ml of
mefloquine (designated Mef 75, Mef 100, Mef
150,Mef 300,Mef 400,Mef 1.2,and Mef 2.4,
respectively,) were derived over an 18-month pe
nod.Selectionlevelsexceeding2,400ng/mlof
mefloquine were not successful because of the
limits of drug solubility. Aliquots of passage lines
that were frozen and stored in liquid nitrogen for
future studies are shown in Figure 1.
Drug susceptibility testing
Parasitestabilateswere thawed and main
tamed in the absence of drug for up to one year
prior to drug susceptibility assays. Parasites were
MATERIALS AND METHODS
The parasite clones W2 and W2-mef, derived
at the University of North Car2Â° were
gifts from Dr. Ayoade Oduola (now of the Uni
versity oflbadan, Ibadan, Nigeria). The W2 clone
was originally obtained by single erythrocyte
micromanipulation from a 50% mixture of the
Sierra Leone I/CDC and Indochina III/CDC par
asite lines. The mefloquine resistant clone W2-
mefwas derived by continuous low-dose meflo
quine pressure from the multidrug-resistant but





(Corning Glass Works, San Francisco, CA) in a
total volume of 5 ml of 6% erythrocyte suspen
sion in RPMI 1640 medium (Sigma, St. Louis,
MO) supplemented with 10% heat inactivated
human plasma, 2 @ig/m1of hypoxanthine (Sigma)
and 28 mM NaHCO3 (Sigma). The erythrocytes
used were human type A-positive collected in
citrate phosphate dextrose (CPD), CPD-A1, or
CPD-Al-Adsol (Fort Bragg, Fayetteville, NC and
American Red Cross, Durham, NC). Cultures
were grown in the absence of antibiotics, gassed
with 5% C02, 5% 02, and 90% N2 (National
Welders, Raleigh, NC), and shaken at 50 rpm in
an environmental orbital incubator (New Bruns
wick Scientific, Edison, NJ) at 37Â°C,or grown as
static cultures at 37Â°C.Morphology and parasit
emia were assessed by microscopic examination
of thin blood smears stained with Leuko-Stat
(Fisher Scientific, Atlanta, GA). Cultures were
routinely diluted into fresh erythrocytes to a 0.1â€”
0.2% parasitemia every 3â€”4days. Final parasit
emia ranged from 4% to 15% depending on the
isolate or clone.
Selection for increased mefloquine resistance
Mefloquine hydrochloride was a gift from the
Division of Experimental Therapeutics, Walter
ng/m@__j
FIGuRE 1. Selection protocol for the derivation of
highly resistant passage lines of Plasmodium falcipa
rum in vitro with mefloquine (Mel) hydrochloride. Par
asite lines shown were stabilated and stored for future
studies.
Thin blood smears were taken every 12 hr for
72 hr. The percent parasitemia was determined
by counting 2,000-10,000 erythrocytes depend
ing on the percent parasitemia of the culture, and
growth curves were constructed. Photographs
were taken with Tungsten Balanced Tech Pan
film (Eastman Kodak, Rochester, NY) on a Ni
kon (Melville, NY) FXA microscope. The orig
inal magnification was either 1,000 x (Figure 2A)
or 1,400 x (Figure 2 Bâ€”F).
Exponential growth rates (R)
The growth rate was analyzed as previously
described by the following equation:
R = in A2â€” in A,
t2 â€”tI
where A, and A2 = the number of parasites per
milliliter of blood at times t, and t2, respec
tively.23
Morphometric studies
To determine the degree of vacuolization of
the parasite clones and lines, the total parasite
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washed two times in medium without exogenous
hypoxanthine, or were cultivated for one week
prior to assay in medium without hypoxanthine
supplementation. The semiautomated microdi
lution technique was used as an index of anti
malarial activity.26 Briefly, 96-well, flat-bot
tomed microtiter plates were prepared with serial
dilutions of drug in duplicate over 520-fold or
1,024-fold concentration ranges. Parasitized
erythrocytes at a 1.5% hematocrit with an initial
parasitemia of 0.25â€”0.4% were added to each
well, the plates were incubated at 37Â°Cin 5%
CO2. 5% 02, and 90% N2 for 24 hr, pulse labeled
with 3H-hypoxanthine (0.5 sCi/well, specific ad
tivity 1 mCi/mM; ICN Biomedicals, Inc., Costa
Mesa, CA) for 18 hr, and harvested at 42â€”44hr
onto glass fiber filters (Whatman LabSales, Hills
boro, OR) using a Mash II cell harvester (MA
Bioproducts, Inc., Walkersville, MD). The 50%,
90%, 95%, and 99% inhibitory concentrations
(IC50, 90@95@and@ reS@3@tively,) of mefloquine
hydrochloride (WRAIR), chloroquine diphos
phate (Sigma), quinine sulfate (Sigma), and hal
ofantrine hydrochloride (WRAIR) were deter
mined by nonlinear regression analysis of
concentration-response data.26
Microscopic assays were also used for an in
dependent determination of inhibitory concen
trations of mefloquine. Briefly, 96-well, flat-bot
tomed microtiter plates (Nunc, Inc., Naperville,
IL) were prepared with serial dilutions of drug
concentrations in triplicate ranging from 1.2 ng/
ml to 1,250 ng/ml of mefloquine. Parasite sus
pensions of a 1.5% hematocrit with an initial
0.2% parasitemia were added, the plates were
gassed, and incubated at 37Â°C.Smears were made
at 44 hr, stained, parasites were counted, and the
inhibitory concentration values were calculated.
Mean IC50 and IC90 determinations were com
pared with data from assays set up simultaneous
ly by the 3H-hypoxanthine microdilution meth
Morphologic growth curves
Growth rate assays were performed on the W2
and W2-mef clones and the Mef 300 and Mef
2.4 passage lines in medium containing meflo
quine at the approximate IC50 (20 ng/ml) and
IC95 (100 ng/ml) level of the Mef 2.4 passage
line. Briefly, 10 ml of 5% hematocrit suspensions
of control and drug-treated cultures were pre






Mef 100 100 ng/ml
Mef 150 150 ng/snl
Mef 300 300 ng/ml




















FIGuRE2. Modified Giemsa-stained thin blood smears demonstrating parasite morphology. A, enlarged
vacuole formation and increased hemozoin production in Mef 2.4 line. The clones W2 (B) and W2-mef(C),
and the passage lines Mef 300 (D) and Mef 2.4 (E) were cultivated in 100 ng/ml of mefloquine hydrochloride.
The Mef 2.4 line was cultivated in 200 ng/ml of mefloquine hydrochloride (F). (Original magnification x 1,000
for A, and x 1,400 for B-F).
and vacuole areas of 25â€”40midstage trophozo- and standard deviation were calculated for W2,
ites were measured using a software morphom- W2-mef, and Mef 2.4.
etry system (Image Measure; Phoenix Technol- . .
ogy, Federal Way, WA) with an image processor Statistical analysis
(FG- 100-AT; Imaging Technology, Woburn, All inhibitory concentration measurements,






per schizont, and growth rates were statistically
analyzed, and presented as mean Â±standard de
viation. A one-way analysis of variance with a
pos hoc contrast to compare group means was
used to evaluate the statistical significance of
measurements.27
RESULTS
Selection for highly resistant parasite lines
The W2-mef clone had exhibited stable me
floquine resistance for three years in the absence
of drug when selection protocols for higher re
sistance levels were initiated. The basic approach
for selection of the progressively resistant pas
sage lines is depicted in Figure 1. Since W2-mef
did not tolerate 40 ng/ml of drug, the final se
lection dosage that was used in the derivation of
this clone,'0 mefloquine pressure was resumed at
a concentration of3O ng/ml. Parasite growth rates
decreased and changes in parasite morphology
were observed for the first several weeks of drug
pressure. Morphologic changes noted in meflo
quine treated cultures included 1) enlargement,
swelling, and occasional pigmentation of the ring
stage cytoplasm, 2) vacuolization, enlargement,
and rarefaction of the chromatin mass, 3) com
pact, small, diffusely stained trophozoites marked
by vacuolization with dispersal of pigment, 4)
mature schizonts that were extremely disorgan
ized with reduced numbers of merozoites that
appeared to be disintegrated, and 5) vacuolated
erythrocytes. After several weeks of passage in
this drug concentration, resistant parasite lines
appeared that were morphologically similar to
parental controls, and exhibited growth rates
equivalent to controls. The mefloqumne concen
tration was then increased. Under the continuous
drug pressure protocols described in the Mate
rials and Methods, parasites adapted to 55 ng/
ml of mefloquine within 20 weeks. Attempts to
isolate lines resistant to levels greater than 55 ng/
ml were unsuccessful.
To circumvent this problem, we initiated re
lapse protocols based on approaches used to
isolate highly resistant MDR tumor cells.'6 Drug
concentrations were increased (see Figure 1 for
parasite lines that were stabilated) as follows.
Initially, parasites were cultivated in the pres
ence of drug for no more than two to three days
when parasitemias decreased below the limits
of detectability (< 0.00 1%). Detection of par
asites in culture generally occurred two to four
days following cessation of drug pressure. By
the fifth re-exposure to drug at concentrations
of 300 ng/ml of mefloquine, parasites survived
for five to seven days prior to decreasing below
detectable limits, and required nine-days in
cubation in drug-free medium before they were
again detected. Parasite lines were eventually
isolated that tolerated doses of 1,200 and 2,400
ng/ml for 14 days with continuedlow-level schi
zogony, after which they were not detectable in
culture until after 3 1-days incubation in the ab
senceofdrug.
Morphologic alterations andgrowth rate analysis
Morphologic alterations on thin blood smears
were observed with the derivation of the Mef
300 line and seen in subsequent parasite lines.
An enlarged vacuole was seen in the trophozoite
stage and at early chromatin division of the
schizont stage (Figure 2A). To document the in
creased vacuolization in Mef 2.4, the total par
asite and vacuole areas ofmidstage trophozoites
of W2, W2-mef, and Mef 2.4 were determined.
The mean Â±SD parasiteareasforW2, W2-mef,
and Mef 2.4were 12.57Â±2.92 @im2,12.19Â±
2.03 @m2,and 12.10 Â±2.10 @Lm2,respectively.
No significant differences were noted among the
means (P = 0.726). The mean Â±SD vacuole
areas of W2, W2-mef, and Mef 2.4 were 0.74 Â±
0.57 @im2,1.59 Â±0.83 @im2,and 5.23 Â±1.73
@m2,respectively. The mean total vacuole area
encompassed 5.9% of the total parasite area of
W2, 13.0% of the area of W2-mef, and 43.2% of
the area of Mef 2.4. Significant increases in total
vacuole area were noted in W2-mef and Mef 2.4
as compared with W2 (P < 0.05), and between
W2-mef and Mef 2.4 (P < 0.001). Increased pig
ment formation was also noted, and has persisted
as a permanent morphologic alteration (Figure
2A).
The exponential growth rates (R values) were
determined for the progenitor clone, W2-mef,
and the Mef 2.4 line. Significant differences were
noted in the mean Â±SD R values for Mef 2.4
(1.89 Â±0.22) as compared with those for W2-
mef(1.34 Â±0.13)(P = 0.05). Merozoite numbers
per schizont were determined to ascertain wheth
er increased merozoite formation had resulted
during the derivation of Mef 2.4. The mean num
ber of merozoites per schizont was not signifi
cantly different among W2 (18.9 Â±1.9), W2-mef
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are means Â±SD of at least three separate determinations (two serial dilutions per determination).
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FIGURE3. Comparative dose-response curves of the clone W2-mef and the passage lines of Plasmodium
fakiparum to mefioquine hydrochloride. In vitro susceptibility profiles of W2-mef (â€¢),Mef 300 (A), Mef 1.2
(a),and Mef 2.4 (Y)weregenerated using 3H-hypoxanthineincorporation as an index of parasite growth. Control




(18.1 Â± 2.5), and Mef 2.4 (20.1 Â± 2.0) (P =
0.116).
Determination of inhibitory concentrations
The dose-responsecurvesoftheW2-mef,Mef
300, Mef 1.2, and Mef 2.4 lines against meflo
quine as determined by 3H-hypoxanthine in
corporation are shown in Figure 3. The dose
response curves of the Mef 1.2 and 2.4 lines
reflect a broadening of the curve that does not
return to baseline even when assayed against
500 ng/ml of mefloquine. The Mef 2.4 line was
a more vigorous parasite line, since the initial
parasitemia had to be significantly reduced (two
fold compared with those of W2 or W2-mef)
for radiometnc assay or parasite overgrowth
significantly affected results. Table 1 lists the
mean Â±SD determinations of the estimated
IC50, 90.95,and@ values for mefloquine against
W2, W2-mef, Mef 300, Mef 1.2, and Mef 2.4.
No significant change in the IC50 was noted in
Mef 300 (P = 0.606), Mef 1.2 (P = 0.764), or
Mef 2.4 (P = 0.704) as compared with W2-mef.
The means of the estimated IC90, 95.and@ val
ues were not significantly different between W2-
mef and Mef 300 (P = 0.175). Significant dif
ferences in these values, however, were noted
in Mef 1.2 and Mef 2.4 as compared with W2-
mef and Mef 300 (P = 0.001). No significant
difference was noted in the IC@ (P = 0.559) or
IC95(P = 0.444) values for Mef 1.2 as compared
with Mef 2.4. The mean IC90values for Mef 1.2
and Mef 2.4 demonstrated a 1.5-fold increase,
and the mean IC95 demonstrated a 1.9-fold in
crease as compared with W2-mef and Mef 300.
The mean IC99 was increased 2.8-fold for Mef
1.2 and 2.3-fold for Mef 2.4 as compared with
TABI@ 1
Comparative in vitro susceptibility profiles of the Plasmodium falciparum clones W2 and W2-mef and the Me@f







Comparison of radiometric and microscopic methods
for determination of estimated inhibitory concentra
tions (IC) of the Plasmodium falciparum Mef 2.4
line against mefloquine*
for Mef 2.4, respectively. These results sug
gested that if a highly resistant subpopulation
were present, it would exhibit a very high IC50,
and would represent a minor percentage of the
parasite population. Determination ofa second
IC50 for a presumed resistant subpopulation,
however, could not be determined with confi
dence.
Growth curve analysis
The results of the radiometric and micro
scopic assays, showing an IC50 value of approx
imately 15 ng/ml of mefloquine, were puzzling
since the parasite lines had demonstrated very
efficient growth in 55 ng/ml ofmefloquine dur
ing isolation ofthe passage series. Growth rates
of mefloquine-sensitive W2, the progenitor
clone, W2-mef, and the passage lines Mef 300
and Mef 2.4 were analyzed in the presence and
absence of drug using conditions that reflected
the original selection protocol (10-mi suspen
sions of a 5% hematocrit). Cultures were inoc
ulated with parasitemias of 1.3â€”1.5%in meflo
quine concentrations ranging from 0 ng/ml to
200 ng/ml. These concentrations were chosen
to approximate the range of IC50 to IC99 values
of Mef 2.4 against mefloquine by radiometric
and microscopic dose-response assays (Tables
1 and 2). The results of these experiments are
shown in Figure 5.
Under conditions in which control cultures
reached maximum parasitemia within 36 hr,
growth of the mefloquine-sensitive W2 clone
was rapidly inhibited in either 20 ng/ml or 100
ng/ml ofmefloquine (Figure 5A). Parasite mor
phology demonstrated collapsed trophozoites
that appeared tight and darkly stained (Figure
2B). Parasitemia decreased to levels less than
0.001% by 72 hr. In contrast, W2-mef, Mef 300,
and Mef 2.4exhibitedgrowthratesequivalent
tountreatedcontrolswhen cultivatedin20 ng/
ml of mefloquine (Figure 5Bâ€”D).The W2-mef
line was rapidly eliminated from culture in the
presence of 50 or 100 ng/ml of mefloquine with
in 3â€”4days (Figure SB). Parasite morphology
demonstrated small, vacuolated, diffusely
stained trophozoites with marked dissolution of
pigment (hemozoin), and schizonts with re
duced numbers of disintegrating merozoites
(Figure 2C). The Mef 300 line grew efficiently
in 50 ng/ml of mefloquine, but exhibited re
duced growth rates in the presence of 100 ng/
the means for W2-mef and Mef 300. These re
suits demonstrated that resistance to meflo
quine in these passage lines had increased sig
nificantly.
Microscopic assays were performed for com
parison since previous studies reported a lack
of correlation between radiometric and micro
scopic assays against mefloquine.9 The IC30and
IC90 values for Mef 2.4 against mefloquine de
termined in parallel by both methods are pre
sented in Table 2. No significant differences were
noted in the mean IC50 or IC90 values obtained
by the two methods (P = 0. 115).
Parasite lines had been derived that clearly
tolerated increased concentrations of meflo
quine, yet their IC50 values were unchanged as
determined by both radiometric and micro
scopic dilution assays. Their elevated IC95 and
IC99 values were consistent with increased re
sistance. We therefore sought to determine
whether mefloquine tolerance resulted from a
small resistant subpopulation that persisted in
culture and accounted for sufficient 3H-hypo
xanthine incorporation to result in the trailing
endpoint of the dose-response curve, but not
enough incorporation to increase the IC50of the
entire culture.
Assay data for the Mef 1.2 and 2.4 lines were
reanalyzed using a modification of the logistic
logarithmic function that permits the evalua
tion of a biphasic concentration-response rela
tionship of a mixed culture.2Â°The results are
shown in Figure 4. The first IC50 values were
similar (13.78 Â±1.08 for Mef 1.2 and 15.58 Â±
1.50 for Mef 2.4) to those presented in Figure
3 and Table 1. The curves had a trailing end
point that did not return to baseline even at a
mefloquine concentration of 1,200 ng/ml (high
er dilutions were not possible because of solu
bility limitations). The values calculated by the
curve-fitting program using the assumption that
the curve would return to baseline were 1,484.18











FIGuRE4. Dose concentrationresponseanalysisoftheA, Mef 1.2and B,Mef 2.4linesofPlasmodium
fakiparum against mefloquine hydrochloride. Dose response was analyzed using a modification of the logistic
logarithmic function that permits evaluation of a biphasic concentration-response relationship.2Â°Control counts
per minute (cpm) ranged from 20,000 to 38,000.
10
ml of mefloquine (Figure SC). Morphology sim
ilar to that described for W2-mef was detected
after cultivation in 100 ng/ml of mefloquine for
three days (Figure 2D). Parasitemia eventually
decreased below limits of detectability (<
0.001%) after one week. The most surprising
result of these studies was the growth of Mef
2.4 at rates equivalent to controls in the pres
ence of 100 ng/ml of mefloquine (Figure SD).
Parasite morphology appeared to be unaffected
by this concentration of drug (Figure 2E); how
ever, the number of merozoites per schizont was
significantly reduced (11.3 Â±1.4 as compared
with 20.1 Â±2.0 for untreated controls; P <
0.00 1). Cultivation of Mef 2.4 in 200 ng/ml of
mefloquine resulted in a reduction in parasite
growth (Figure SD). Although merozoite num
bers were greatly reduced (6.8 Â±1.9 as com
pared with 20.1 Â±2.0 for untreated controls: P
<0.001), schizont formation continued at these
drug levels (Figure 2F).
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FIGURE 5. Growth curves of A, the mefloquine-sensitive clone W2, B, the mefloquine-resistant clone W2-
mef, C, the Mef 300 line, and D, the Mef 2.4 line of Plasmodiumfakiparum cultivated in the presence of 0 ng/
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Fifty percent inhibitory concentration (ICSG)determinations for chloroquine diphosphate, halofantrine hydrochlo
ride, and quinine sulfate with Plasmodium falciparum clones, W2 and W2-mef and the Mef 2.4 line*
Cross-resistance
Since an approximate 1.4-fold increased sus
ceptibility to chloroquine and an approximate
2.3-fold increased resistance to halofantrine were
noted in the W2-mef line compared with its
multidrug-resistant parent â€˜Â°drug suscep
tibility to chloroquine, quinine, and halofan
trine was assayed in the resistant passage lines.
The IC50 determinations for W2, W2-mef, and
Mef 2.4 against chloroquine diphosphate, qui
nine sulfate, and halofantrine are shown in Ta
ble 3. These data indicated little difference in
susceptibility to quinine in the Mef 2.4 line as
compared with W2 and W2-mef (P = 0.199).
In contrast, the estimated IC50 determinations
indicated a 1.3-fold increased sensitivity to
chloroquine (P < 0.05), and an approximate
2.3-fold increased resistance to halofantrine (P
< 0.05) as compared with W2-mef.
DISCUSSION
A series of progressively more resistant lines
of P. fakiparum was isolated by cultivation in
mefloquine concentrations ranging from 30 ng/
ml to 2,400 ng/ml. Parasite lines were derived
that grow efficiently in 100â€”200ng/ml, and that
tolerated concentrations of 2,400 ng/ml for ex
tended periods. Persistence in 2,400 ng/ml for
periods of up to 14 days with low level schizog
ony suggested that the parasite could tolerate in
vitro dosages approaching the mean Â±SD peak
plasma concentrations (1.12 Â±0.3 @ig/ml)mea
sured in humans following a 1,500-mg dose.28
To our knowledge, no other mefloquine-resistant
lines have been derived that tolerate drug doses
invitrothatapproachpharmacologiclevelsin
humans.
The apparent increased resistance of the pas
sage lines to mefloquine under culture conditions
was not confirmed by increased IC50 determi
nations generated by radiometric or microscopic
assays. Comparison ofthe growth curves (Figure
5) with the assay data (Tables 1 and 2) suggests
a likely explanation for this anomaly. The 3H-
hypoxanthine assay used 1.5% hematocrit sus
pensions, while growth curve analysis used 5%
hematocrit suspensions, which were also used in
maintenance cultures and drug selection proto
cols. Since mefloquine has been found to bind
extensively to phospholipids and erythrocyte
membranes with high affinity,29 and to hemo
globin with low affinity,30 the percent hematocrit
can greatly alter drug bioavailability to the par
asite.
The dose-response curve has been shown to
be dramatically modulated by an increased per
cent â€˜â€˜,@ â€T̃he results of growth rate
analysis using 5% hematocrit suspensions clear
ly indicated that lines had been derived that
demonstrated increased resistance as compared
with the W2-mef clone. The Mef 300 line grew
in SO ng/ml of mefloquine while W2-mef did
not, and the Mef2.4 line grew in concentrations
(100â€”200 ng/ml) that significantly inhibited Mef
300. These results supported those ofa previous
study, which demonstrated a three-fold dis
crepancy between IC50 determinations mea
sured by microscopic versus radiometric assays
in different percent hematocrit suspensions.9 Our
results also suggest that growth rate analysis us
ing suspensions of higher hematocrit may better
predict resistance to mefloquine, and perhaps
other extremely lipophilic drugs, under physi
ologic conditions. Interestingly, researchers in
a Thai study were unable to use in vitro sus
ceptibility profiles of pretreatment isolates (gen
crated by 3H-hypoxanthine assays) to predict
subsequent mefloquine treatment failures.6
The increased vacuole formation observed in
parasite lines with dosages exceeding 300 ng/ml
was consistent with studies that demonstrated
rapid swelling of the parasite food vacuole fol
lowing exposure to extremely high (50 @ig/ml)
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concentrations of mefloquine.32 Although slight
vacuolization is seen at times during in vitro
cultivation ofP.fakiparum, the Mef2.4 line has
produced significantly larger vacuoles (43% of
the total parasite area) than those seen in other
clones and lines cultivated in the laboratory. It
is interesting to note that increased vacuolization
and increased numbers of lysosome-like vacu
oles have been noted in MDR tumor cell lines
following selection with cytotoxic concentrations
of lipophilic antitumor agents.â€• A hypothesis
offered to explain these findings in MDR tumor
cells is that vesicular compartmentalization and
altered targeting of drug away from cellular tar
gets may play a role in drug resistance mecha
nisms.34
Increased growth rates have been associated
with the development of resistant parasites in
vitro and in vivo,35 although it is not clear what
parasite processes contribute to this phenome
non. The increased growth demonstrated by the
Mef2.4 line could not be attributed to increased
merozoite production since merozoite forma
tion was not significantly different from either
W2 or W2-mef. An abbreviated life cycle, and!
or enhanced invasion of erythrocytes may con
tribute to enhanced growth. Enhanced pigment
production may also be associated with in
creased growth since rapidly metabolizing par
asites may sequester increased amounts of he
mozoin.Alternatively,itmay beassociatedwith
an altered heme polymerase activity. This en
zyme is thought to function in the sequestration
of the toxic heme moiety, ferriprotoporphyrin
IX, by polymerizing it into hemozoin.36'37
Chioroquine, amodiaquine, and quinidine have
been shown to block heme polymerization in
vitro, suggesting that this enzyme may be a tar
get for quinoline-containing antimalarials.37
A current controversial hypothesis is that re
sistance to chloroquine and mefloquine in P.
fakiparum may be similar to the MDR phe
notype described in MDR tumor cell lines.38
The classic MDR phenotype characterized by
changes in sensitivity to a broad spectrum of
related and unrelated drugs, however, has not
yet been established in P. fakiparum. A single
well-documented exception may be the in vitro
induction of mefloquine resistance in the mul
tidrug-resistant clone, W2, which resulted in al
tered susceptibility patterns to chloroquine and
its analogue halofantrine, which are drugs with
in the same broad chemical class.'0 The den
vation of the Mef 2.4 line from W2-mef also
resulted in additional increases in sensitivity to
chloroquine and resistance to halofantrine, pro
viding additional support for these findings. Al
though susceptibility levels to both compounds
remained well above levels correlated with re
sistance in vivo,5 â€˜â€t̃hese findings suggest that
an MDR-like phenotype had been derived in
these lines. Alternatively, cross-resistance to
halofantrine and susceptibility to chloroquine
may be mediated by other mechanisms since
effiux of mefloquine has not yet been demon
strated in P. fakiparum.
The MDR phenotype has been especially dif
ficult to document in vivo since individuals may
be coinfected with singly or multiple drug-re
sistant strains that may be preferentially select
ed during treatment regimens. Nevertheless,
several interesting observations have been not
ed in the field following treatment failures.46'@
A treatment failure with enpiroline in an cx
perimental volunteer yielded a post-treatment
isolate with increased resistance to halofantrine
and mefloquine, and increased susceptibility to
chloroquine and quinine.5 Analysis of recru
descent parasites following treatment failures
with mefloquine in Thailand have also dem
onstrated significant increases in the in vitro
resistance to mefloquine, halofantrine, and en
piroline, and significant increases in sensitivity
to chloroquine.6'39These findingsimply that
resistance mechanisms to mefloquine and hal
ofantrine developed by Mef 2.4 in vitro may be
similar to mechanisms of resistance that de
velop in vivo.
Currently, there are few in vitro models avail
able to study the acquisition of antimalarial re
sistance that may be correlated with the patterns
of resistance emerging in field settings. Our re
sults suggest that not only does the Mef 2.4 model
mimic drug susceptibility profiles noted in re
crudescent parasites in vivo,5'6'39 but also ap
pears to parallel, at least in part, the MDR phe
notype seen in mammalian tumor cell lines.
Progressively resistant parasite lines that tol
erate pharmacologic doses of mefloquine pro
vide a unique model system to examine poten
tial biological and molecular processes that may
relate to mefloquine resistance. Important areas
of investigation with these lines include 1) the
study of cross-resistance and collateral sensitiv
ity to related and unrelated compounds, 2) the
capacityofreversalagentstorestoretheefficacy
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